EGFR and neoplasm: In “negative hyperselected” patients, the absence of resistance-associated mutations (e.g., KRAS, NRAS, BRAF V600E, and EGFR extracellular domain mutations) ensures that the EGFR pathway remains a primary driver of tumor progression, making these tumors more susceptible to EGFR blockade.